Biolegend, 307202, Purified anti-human CD261 (DR4, TRAIL-R1) Antibody, 100μg

DR4 is 56 kD member 10A of the TNFR superfamily (TNFRSF10A), also known as TRAIL-R1, Apo-2, and CD261. It is expressed at low levels by activated T cells and some tumors. After TRAIL engagement, DR4 (TRAIL-R1), through activation of NF-κB, induces apoptosis in the TRAIL ligated cell.
100μg
Verified Reactivity: Human
Reported Reactivity: African Green, Cynomolgus
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Extracellular domain of DR4-human IgG1 Fc fusion protein
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Additional reported applications (for the relevant formats) include: The DJR1 antibody is useful for immunofluorescent staining and flow cytometric analysis of DR4/TRAIL-R1 receptor expression. For most successful immunofluorescent staining results, it may be important to maximize signal over background by using a relatively bright fluorochrome-antibody conjugate (Cat. No. 307206) or by using a high sensitivity, three-layer staining technique (e.g., including a biotinylated antibody or biotinylated anti-mouse IgG second step (Cat. No. 405303), followed by SAv-PE (Cat. No. 405204)).
Application References(PubMed link indicates BioLegend citation): Uno K, et al. 2003. Blood 101:3658. Sato K, et al. 2005. J. Immunol. 174:4025. Lundqvist A, et al. 2006. Cancer Res. 66:7317. PubMed Chen KF, et al. 2011. J Pharmacol Exp Ther. 337:155. PubMed Sonnemann J, et al. 2012. Cancer Biol Ther. 13:417. PubMed Chandrasekaran S, et al. 2014. PLoS One. 9:111487. PubMed
Product Citations: Sonnemann J, et al. 2012. Cancer Biol Ther. 13:417. PubMed Winterberg D, et al. 2021. J Clin Med. 10:. PubMed Chandrasekaran S, et al. 2014. PLoS One. 9:111487. PubMed Chen K, et al. 2011. J Pharmacol Exp Ther. 337:155. PubMed Lundqvist A, et al. 2006. Cancer Res. 66:7317. PubMed
RRID: AB_314665 (BioLegend Cat. No. 307201) AB_314666 (BioLegend Cat. No. 307202)
Structure: TNFR superfamily, 56 kD
Distribution: Activated T cells, tumor cells
Function: Induces apoptosis
Ligand/Receptor: TRAIL
Cell Type: T cells
Biology Area: Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Immunology
Molecular Family: CD Molecules, Cytokine/Chemokine Receptors
Antigen References: 1. Macfarlane M. 2003. Toxicol. Lett. 139:89. 2. Baetu T, et al. 2002. Cytokine Growth Factor Rev. 13:199. 3. Degli-Esposti M. 1999. J. Leukoc. Biol. 65:535.
Gene ID: 8797
UniProt: View information about CD261 on UniProt.org
Clone: DJR1
Regulatory Status: RUO
Workshop: HCDM listed
Other Names: TRAIL-R1, Apo-2, CD261, TNFRSF10A
Isotype: Mouse IgG1, κ